More than 90 percent of voting Transgenomic shareholders gave the go-ahead to the deal. Upon completion of the merger, the new firm will take on the Precipio name.
The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.
JoyingBio will distribute Transgenomic's multiplexed ICE COLD-PCR kits in China and Biotron Healthcare will do the same in India.
The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.
The firm's labs services revenues were unchanged, but it saw a slight increase in sales mainly from higher oncology revenue and grants.
Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
The partners will augment the multiplexing capabilities of ICE COLD-PCR, which was developed at Dana-Farber and is exclusively licensed to Transgenomic.
The lower sales from contract laboratory services reflect Transgenomic's continued refocusing on its core ICE-COLD PCR molecular diagnostic technology.
The deal covers four of Transgenomic's liquid biopsy cancer assays, which detect actionable mutations associated with sensitivity or resistance to therapy.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.